{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:30:50Z","timestamp":1792240250113,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.intimp.2024.113934","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T09:47:17Z","timestamp":1737280037000},"page":"113934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Innate and SARS-CoV-2 specific adaptive immune response kinetic in neutralizing monoclonal antibody successfully treated COVID-19 patients"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7574-8780","authenticated-orcid":false,"given":"Rita","family":"Casetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-7504","authenticated-orcid":false,"given":"Valentina","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Cristofanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germana","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Gili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cimini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Notari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Bordoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-662X","authenticated-orcid":false,"given":"Ilaria","family":"Mastrorosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Giancola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vergori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Tempestilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Lalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Meschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Colavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rosa","family":"Garbuglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Nicastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Agrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113934_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.576745","article-title":"ACE2\/ADAM17\/TMPRSS2 interplay may be the main risk factor for COVID-19","volume":"11","author":"Zipeto","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2024.113934_b0010","article-title":"SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release","author":"Junqueira","year":"2021","journal-title":"Res. Sq."},{"key":"10.1016\/j.intimp.2024.113934_b0015","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cvr\/cvaa106","article-title":"COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options","volume":"116","author":"Guzik","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.intimp.2024.113934_b0020","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.3390\/jcm10214802","article-title":"Infection of Human Cells by SARSCoV-2 and molecular overview of gastrointestinal, neurological, and hepatic problems in COVID-19 patients","volume":"10","author":"Rahban","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2024.113934_b0025","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/cid\/ciaa577","article-title":"An inflammatory profile correlates with decreased frequency of cytotoxic cells in coronavirus disease 2019","volume":"71","author":"Bordoni","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.intimp.2024.113934_b0030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2024.113934_b0035","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.113934_b0040","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.intimp.2024.113934_b0045","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group, P. Horby, W.S. Lim, J.R. Emberson, M. Mafham, J.L. Bell, L. Linsell, N. Staplin, C. Brightling, A. Ustianowski, et al., Dexamethasone in hospitalized patients with Covid-19, N. Engl. J. Med. 384 (2021) 693\u2013704, doi:10.1056\/NEJMoa2021436.","DOI":"10.1056\/NEJMoa2021436"},{"key":"10.1016\/j.intimp.2024.113934_b0050","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2665-9913(21)00216-2","article-title":"Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis","volume":"3","author":"Kyriazopoulou","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.intimp.2024.113934_b0055","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2024.113934_b0060","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.113934_b0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.113934_b0070","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.113934_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258154","article-title":"Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: a population-based cohort study","volume":"16","author":"Ge","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.113934_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.868020","article-title":"Emulation of a target trial from observational data to compare effectiveness of casirivimab\/imdevimab and bamlanivimab\/etesevimab for early treatment of non-hospitalized patients with COVID-19","volume":"13","author":"Mazzotta","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2024.113934_b0085","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"BLAZE-1 investigators, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2020","key":"10.1016\/j.intimp.2024.113934_b0090","first-page":"497","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.113934_b0095","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41418-020-0572-6","article-title":"Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)","volume":"27","author":"Agrati","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.intimp.2024.113934_b0100","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2024.113934_b0105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2355-0","article-title":"Viral and host factors related to the clinical outcome of COVID-19","volume":"583","author":"Zhang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.113934_b0110","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","article-title":"A dynamic COVID-19 immune signature includes associations with poor prognosis","volume":"26","author":"Laing","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2024.113934_b0115","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2024.113934_b0120","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1038\/s41467-020-17292-4","article-title":"Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia","volume":"11","author":"De Biasi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.113934_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.735125","article-title":"Persistent high percentage of HLA-DR+CD38high CD8+ T Cells associated with immune disorder and disease severity of COVID-19","volume":"12","author":"Du","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2024.113934_b0130","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.4049\/jimmunol.2001034","article-title":"T cell phenotyping in individuals hospitalized with COVID-19","volume":"206","author":"Rupp","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.113934_b0135","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1038\/s41467-020-17240-2","article-title":"Immunological and inflammatory profiles in mild and severe cases of COVID-19","volume":"11","author":"Song","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.113934_b0140","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13102","article-title":"Perforin, COVID-19 and a possible pathogenic auto-inflammatory feedback loop","volume":"94","author":"Cunningham","year":"2021","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2024.113934_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.610300","article-title":"Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases","volume":"11","author":"Carsetti","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2024.113934_b0150","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijid.2020.05.106","article-title":"Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity","volume":"97","author":"Kang","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.intimp.2024.113934_b0155","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jneuroim.2007.11.010","article-title":"Correlation of specialized CD16(+) gammadelta T cells with disease course and severity in multiple sclerosis","volume":"194","author":"Chen","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2024.113934_b0160","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/icb.2017.6","article-title":"Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells","volume":"95","author":"Ochoa","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.intimp.2024.113934_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790469","article-title":"Endogenous antibody responses to SARS-CoV-2 in patients with mild or moderate COVID-19 who received bamlanivimab alone or bamlanivimab and etesevimab together","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2024.113934_b0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijid.2022.09.016","article-title":"Spike-specific T-cell responses in patients with COVID-19 successfully treated with neutralizing monoclonal antibodies against SARS-CoV-2","volume":"124","author":"Rotundo","year":"2022","journal-title":"Int. J. Infect Dis."},{"key":"10.1016\/j.intimp.2024.113934_b0195","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1182\/bloodadvances.2020003568","article-title":"A neutrophil activation signature predicts critical illness and mortality in COVID-19","volume":"5","author":"Meizlish","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2024.113934_b0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2024.113934_b0205","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/imm.13487","article-title":"The immune response to COVID-19: does sex matter?","volume":"166","author":"Ho","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2024.113934_b0210","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-020-2700-3","article-title":"Sex differences in immune responses that underlie COVID-19 disease outcomes","volume":"588","author":"Takahashi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.113934_b0215","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1038\/s41467-020-19080-6","article-title":"Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19","volume":"11","author":"Carissimo","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.113934_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102314","article-title":"Role of NKG2a\/c+CD8+ T cells in pathogenic versus non-pathogenic SIV infections","volume":"24","author":"Huot","year":"2021","journal-title":"iScience"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924024561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924024561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:55:08Z","timestamp":1740617708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924024561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":40,"alternative-id":["S1567576924024561"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113934","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innate and SARS-CoV-2 specific adaptive immune response kinetic in neutralizing monoclonal antibody successfully treated COVID-19 patients","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113934"}}